SOURCE: MultiCorp International, Inc.

March 31, 2015 09:00 ET

MultiCorp International, Inc. Engages Compass Point Research to Collaborate With NDA Partners to Develop Patented Migraine Combination Drug

Company Engages NDA Partners and Compass Point Research to Finalize Submission for Meeting With FDA

SUN VALLEY, CA--(Marketwired - Mar 31, 2015) - MultiCorp International, Inc, (OTC PINK: MCIC) has engaged Compass Point Research of Nashville, Tennessee to manage the product development program, and NDA Partners, of Rochelle, Virginia will provide the drug development and regulatory expertise needed to prepare a development plan for a 505(b)(2) NDA submission to the US Food & Drug Administration (FDA) and to manage a pre IND meeting with the FDA review division.

The company released the following statement, "We've spent the last year reviewing and evaluating the best path for the company to take in order to submit the migraine medicine for the company to gain acceptance and approval from the FDA for the patented migraine medicine. Notwithstanding our previous work with another firm, we feel we've made the proper decision in order to move forward with Compass Point Research and NDA Partners. Their extensive experience in drug development and overall management of the FDA submission process will put MultiCorp in a position to capitalize on the opportunities the migraine medicine may bring." stated Mr. Paul D. Lisenby, CEO of MultiCorp International, Inc. Mr. Lisenby further stated, "Compass Point has assembled an outstanding team to help us develop a clear path towards FDA submission and approval, and we look forward to working with them to fill this important medical need."

About Compass Point Research
Compass Point Research is a full-service clinical and translational research management and consulting firm. The company's focus is on facilitating all aspects of clinical trials operations for community-based healthcare providers, including drug, device, nutritional supplement and consumer product development from discovery through clinical studies, and post-approval support. In addition, Compass Point develops and coordinates multi-center outcomes and registry trials for industry sponsors, healthcare providers and payers, delivering scientifically rigorous research outcomes in an affordable environment. The company has been able to assist providers with not only eliminating a subsidy for research, but actually realizing a net profit for the department or cost center while adhering to all governing regulations and internal standard operating procedures.
http://compasspointresearch.com/index.php

About NDA Partners
NDA Partners is a strategy consulting firm specializing in expert product development and regulatory advice to the medical products industry and associated service industries such as law firms, investment funds and government research agencies. The highly experienced Principals and Premier Experts of NDA Partners include two former FDA Center Directors; the former Chairman of the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK; an international team of approximately 60 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, expert consulting, high-impact project teams, and virtual product development teams.
http://www.ndapartners.com/

About MultiCorp International, Inc.
MultiCorp International, Inc is a diverse company that operates in various business sectors that show true growth potential. The company builds on its executives experience in property development, constructions, medical, hospitality, agribusiness, commodities such as oil and gas, and entertainment. The company looks to expand through acquisitions of solid business models and management that have the potential to grow exponentially. The company will have additional subsidiaries that will eventually grow into being their own public entity, be sold, or continue to operate within MultiCorp. For further information please contact them at info@multicorpinternational.com

Forward-Looking Statements
This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets.

Contact Information